Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. Available from: http://goldcopd.org/. Accessed May 20, 2019.
   Google Scholar
• American Lung Association Epidemiology and Statistics Unit. Trends in COPD (Chronic bronchitis and emphysema): morbidity and mortality 2013. Available from: https://www.lung.org/getmedia/4f74781e-481f-4f10-9255-8dfc9dc56974/copd-trend-report.pdf.pdf. Accessed October, 2020.
   Google Scholar
• Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(3):228–237. doi:10.1164/rccm.201210-1843CI
   PubMed Web of Science ®Google Scholar
• Rogers DF. The role of airway secretions in COPD: pathophysiology, epidemiology and pharmacotherapeutic options. COPD. 2005;2(3):341–353. doi:10.1080/15412550500218098
   PubMedGoogle Scholar
• Saetta M, Turato G, Baraldo S, et al. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med. 2000;161(3 Pt 1):1016–1021. doi:10.1164/ajrccm.161.3.9907080
   PubMed Web of Science ®Google Scholar
• Kim V, Han MK, Vance GB, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011;140(3):626–633. doi:10.1378/chest.10-2948
   PubMed Web of Science ®Google Scholar
• Braman SS. Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):104S–115S. doi:10.1378/chest.129.1_suppl.104S
   PubMed Web of Science ®Google Scholar
• Rogers DF, Barnes PJ. Treatment of airway mucus hypersecretion. Ann Med. 2006;38(2):116–125. doi:10.1080/07853890600585795
   PubMed Web of Science ®Google Scholar
• Choi JY, Yoon HK, Shin KC, et al. CAT score and SGRQ definitions of chronic bronchitis as an alternative to the classical definition. Int J Chron Obstruct Pulmon Dis. 2019;14:3043–3052. doi:10.2147/COPD.S228307
   PubMed Web of Science ®Google Scholar
• Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009;135(4):975–982. doi:10.1378/chest.08-2062
   PubMed Web of Science ®Google Scholar
• Lahousse L, Seys LJM, Joos GF, Franco OH, Stricker BH, Brusselle GG. Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease. Eur Respir J. 2017;50:2. doi:10.1183/13993003.02470-2016
   Web of Science ®Google Scholar
• de Oca MM, Halbert RJ, Lopez MV, et al. The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur Respir J. 2012;40(1):28–36. doi:10.1183/09031936.00141611
   PubMed Web of Science ®Google Scholar
• Kim V, Crapo J, Zhao H, et al. Comparison between an alternative and the classic definition of chronic bronchitis in COPDGene. Ann Am Thorac Soc. 2015;12(3):332–339. doi:10.1513/AnnalsATS.201411-518OC
   PubMed Web of Science ®Google Scholar
• Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–1192. doi:10.1056/NEJMoa1105482
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385(9971):857–866. doi:10.1016/S0140-6736(14)62410-7
   PubMed Web of Science ®Google Scholar
• Sunovion Pharmaceuticals Inc. Lonhala Magnair (Glycopyrrolate) Inhalation Solution: [Package Insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc, 2019.
   Google Scholar
• Kerwin E, Donohue JF, Goodin T, Tosiello R, Wheeler A, Ferguson GT. Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. Respir Med. 2017;132:238–250. doi:10.1016/j.rmed.2017.07.011
   PubMed Web of Science ®Google Scholar
• Kerwin EM, Murray L, Niu X, Dembek C. Clinically important deterioration among patients with Chronic Obstructive Pulmonary Disease (COPD) treated with nebulized glycopyrrolate: a post hoc analysis of pooled data from two randomized, double-blind, placebo-controlled studies. Int J Chron Obstruct Pulmon Dis. 2020;15:2309–2318. doi:10.2147/COPD.S267249
   PubMed Web of Science ®Google Scholar
• Jones PW. St. George’s respiratory questionnaire: MCID. COPD. 2005;2(1):75–79. doi:10.1081/copd-200050513
   PubMedGoogle Scholar
• Leidy NK, Murray LT, Monz BU, et al. Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms tool (E-RS) in three clinical trials. Respir Res. 2014;15:124. doi:10.1186/s12931-014-0124-z
   PubMed Web of Science ®Google Scholar
• Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11(1):122. doi:10.1186/1465-9921-11-122
   PubMed Web of Science ®Google Scholar
• Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry. 2013;170(7):723–733. doi:10.1176/appi.ajp.2012.12040474
   PubMed Web of Science ®Google Scholar
• Rogers DF. Pharmacological regulation of the neuronal control of airway mucus secretion. Curr Opin Pharmacol. 2002;2(3):249–255. doi:10.1016/s1471-4892(02)00146-7
   PubMed Web of Science ®Google Scholar
• Kerwin E, Ferguson GT. An overview of glycopyrrolate/eFlow(R) CS in COPD. Expert Rev Respir Med. 2018;12(6):447–459. doi:10.1080/17476348.2018.1476853
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Distribution of receptor targets in the lung. Proc Am Thorac Soc. 2004;1(4):345–351. doi:10.1513/pats.200409-045MS
   PubMedGoogle Scholar
• Ikeda T, Anisuzzaman AS, Yoshiki H, et al. Regional quantification of muscarinic acetylcholine receptors and beta-adrenoceptors in human airways. Br J Pharmacol. 2012;166(6):1804–1814. doi:10.1111/j.1476-5381.2012.01881.x
   PubMed Web of Science ®Google Scholar
• Pham S, Ferguson GT, Kerwin E, Goodin T, Wheeler A, Bauer A. In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution. J Aerosol Med Pulm Drug Deliv. 2018;31(3):162–169. doi:10.1089/jamp.2017.1384
   PubMed Web of Science ®Google Scholar
• Kim V, Zhao H, Regan E, et al. The St. George’s respiratory questionnaire definition of chronic bronchitis may be a better predictor of COPD exacerbations compared with the classic definition. Chest. 2019;156(4):685–695. doi:10.1016/j.chest.2019.03.041
   PubMed Web of Science ®Google Scholar